Medtronic's MiniMed 670G - the closest thing yet to an artificial pancreas - has been launched in the US. The so-called 'hybrid closed-loop' system comprises a blood glucose sensor ...

The MiniMed 780G automated insulin delivery system with the Simplera Sync CGM. [Image courtesy of Medtronic] Medtronic (NYSE:MDT) announced today that it intends to separate its Diabetes business into ...

Global medical device company Medtronic announced Wednesday that it intends to separate its diabetes business into a standalone company. The new diabetes company will focus on accelerating ...

Medtronic has announced plans to separate out its diabetes business into a new standalone company. The separation will serve to create an “independent, scaled leader in diabetes” that boasts ...

Medtronic expects the separation of its diabetes business to be immediately profitable and improve margins, as diabetes devices require unique commercial and manufacturing strategies. The company ...

Medtronic PLC announced Wednesday plans to separate its diabetes business into a new public company, just as the medical-device company reported quarterly results showing that the business was its ...

Under Medtronic’s plan, the new unnamed company will also be publicly traded, Medtronic said. The diabetes business generated nearly $2.8 billion in sales in its most recent fiscal year ...

After working for years to turn around its diabetes business, Medtronic announced plans on Wednesday to spin out the unit. The decision raised questions among analysts about why Medtronic would exit a ...

Medtronic said Wednesday that it plans to spin off its diabetes business in the next 18 months, creating a new diabetes technology company that can offer customers both insulin pumps and continuous ...

Update: The article updates with a press release from Medtronic. Medical device manufacturer Medtronic (NYSE:MDT) plans to separate its diabetes business into a stand-alone company. The new ...